Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-28T07:23:08.401Z Has data issue: false hasContentIssue false
  • English
  • Français

Atypical antipsychotic monitoring in the Kilkenny Mental Health Services

Published online by Cambridge University Press:  13 June 2014

Larkin Feeney  and
Mary Mooney
Mary Mooney
Affiliation:
Department of Psychiatry, St Luke's Hospital, Kilkenny, Co Kilkenny, Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: To examine baseline testing and ongoing monitoring of cardiovascular and other risk factors in individuals prescribed atypical antipsychotic medications.

Methods: We derived a list of baseline and ongoing monitoring tests from the literature (Weight, BMI, blood pressure, U&E, LFTs, glucose, HbA1C, FBC, TFTs, prolactin, lipids & ECG) and then reviewed a random sample of 80 records of patients prescribed atypical antipsychotics and currently attending an Irish public catchment area service, for evidence of testing.

Results: Levels of testing for baseline tests ranged from 45% for blood pressure to 0% for BMI. Levels of ongoing monitoring tests ranged from 42.5% for U&E to 0% for BMI. Patients admitted to hospital were much more likely to have had testing.

Conclusions: The need for baseline and ongoing monitoring of certain tests in patients prescribed atypical antipsychotics is increasingly accepted. Levels of such testing are currently quite low and need to increase.

Keywords

Atypical antipsychotic monitoringBaseline testingMental health services
Type
Audit
Information
Irish Journal of Psychological Medicine , Volume 22 , Issue 3 , September 2005 , pp. 101 - 102
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Almeras, N, Despres, JP, Villeneuve, J, Demers, MF, Roy, MA, Cadrin, C, Mottard, JP, Bouchard, RH. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004; 65(4): 557–64.CrossRefGoogle ScholarPubMed
2.Meyer, JM, Koro, CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004; 70 (1):1–17.CrossRefGoogle Scholar
3.Nasrallah, HA, Newcomer, JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004; 24(5 Supp 1), S7–14.CrossRefGoogle ScholarPubMed
4.Chue, P, Kovacs, CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord 2003; 5 (2): 62–79.CrossRefGoogle ScholarPubMed
5.Marder, SR, Essock, SM, Miller, AL, Buchanan, RW, Casey, DE, Davis, JM, Kne, JM, Liebermn, JA, Schooler, NR, Covell, N, Stroup, S, Weisman, EM, Wirshing, DA, Hall, Cs, Pogach, L, Pi-Sunyer, X, Bigger, JT Jr, Friedman, A, Kleinberg, D, Yevich, SJ, Davis, B, Shon, S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161 (8): 1334–1349.CrossRefGoogle ScholarPubMed
6.Taylor, D, Paton, C, Kerwin, R. The Maudsley 2003 Prescribing Guidelines. London: Martin Dunitz, 2003.CrossRefGoogle Scholar
7.Kane, JM, Leucht, S, Carpenter, D, Docherty, JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64(12): 5–19.Google ScholarPubMed
8.Dinan, TG and expert group. “Schizophrenia and diabetes 2003” Expert consensus meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry 2004; 184 (suppl. 47): s112–s114.Google Scholar